APOTEX CORP. for APOTEX CORP.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Centers for Medicare and Medicaid Services Rule 2238-P concerning Medicaid Drug Reimbursement H.R. 3700 & S. 1951, the Fair Medicaid Drug Pricing Act
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Pharmacy PHA
S. 316, the Preserve Access to Affordable Pharmaceuticals Act H.R. 1902, the Protecting Consumer Access to Generic Drugs Act H.R. 1038, the Access to Life Savings Medicine Act H.R. 5629, the Pathway for Biosimilars Act S. 1695, the Biologivs Price Competition and Innovation Act H.R. 5829, the Safeguarding America's Pharmaceuticals Act H.R. 3610, the Food and Drug Import Safety Act, Section 4 User Fees Regarding Drug Safety PL 110-85, the Food and Drug Amendments Act of 2007, Title VIII Clinical Trials Abbreviated New Drug Applicatin No. 76-396 for calcitonin salmon nasal spray
Foreign entity interest: ApoSherm Inc., the parent company of Apotex Corp., has direct or indirect ownership interests in companies that develop, manufacture, and/or sell generic drugs, and therefore has an interest in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.